The Zacks Analyst Blog Highlights: Actelion, Bayer, Pfizer, Gilead Sciences and Honeywell International

 The Zacks Analyst Blog Highlights: Actelion, Bayer, Pfizer, Gilead Sciences
                         and Honeywell International

PR Newswire

CHICAGO, Nov. 6, 2013

CHICAGO, Nov. 6, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include  the Actelion Ltd.
(OTC:ALIOF-Free Report), Bayer (OTC:BAYRY-Free Report) Pfizer Inc.
(NYSE:PFE-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report) and
Honeywell International Inc (NYSE:HON-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Tuesday's Analyst Blog:

U.S. Launch of Actelion Hypertension Med

Actelion Ltd. (OTC:ALIOF-Free Report) announced the launch of Opsumit 10 mg in
the U.S. for the treatment of patients suffering from pulmonary arterial
hypertension (PAH WHO Group I) to delay disease progression. Disease
progression includes events like death, commencement of intravenous or
subcutaneous prostanoids or clinical worsening of PAH.

The SERAPHIN study established the effectiveness of Opsumit in PAH patients
with predominantly WHO Functional Class II-III symptoms treated for an average
of 2 years. Opsumit was approved by the U.S. Food and Drug Administration on
Oct 18, 2013

The approval of the drug in the EU for the PAH indication is also on track.
Last month, Actelion received a positive opinion from the Committee for
Medicinal Products for Human Use (CHMP) for Opsumit. Actelion is looking to
get Opsumit approved in the EU as monotherapy or in combination, for the
long-term treatment of PAH in adults of WHO functional class II to III. A
final decision on Opsumit should be out by year end. It has also filed for
approval in other regions.

Opsumit is also being evaluated in a pivotal phase III program in patients
suffering from digital ulcers associated with systemic sclerosis. Results from
this study are expected in the first half of 2014. In addition, Opsumit is
being evaluated for the treatment of glioblastoma (phase I).

We believe the launch of Opsumit in the U.S. will strengthen Actelion's
cardiovascular portfolio. Opsumit is the first drug to have proved its
efficacy in delaying disease progression over the long term in PAH patients.
However, the PAH market looks extremely competitive with the presence of
Bayer's (OTC:BAYRY-Free Report) Adempas, Pfizer Inc.'s (NYSE:PFE-Free Report)
Revatio and Gilead Sciences Inc.'s (Nasdaq:GILD-Free Report) Letairis.

Actelion carries a Zacks Rank #1 (Strong Buy) while Bayer is a Zacks #2 (Buy)
Ranked stock.

Refinery Modernization by Honeywell

Honeywell International Inc (NYSE:HON-Free Report) was recently selected by
Swedish oil producer Preem AB to modernize one of Europe's largest refineries.
Honeywell's Enhanced High Performance Process Manager (EHPM) industrial
process controllers will help Preem to upgrade the refinery and increase
through-put while maximizing legacy investments and intellectual property. The
upgrade is expected to be complete before the end of this year.

Additionally, the adoption of other technologies by Honeywell can also be used
by Preem to enhance its overall refinery operations. These include continuous
and batch processing controls such as Experion C300, and Honeywell's fault
tolerant ethernet FTE technology that offer faster network diagnostics and
improved security.

The technological up-gradation is cost effective for the company as it saves
on time and cost of entire control system replacement. The project should
considerably extend the life of the existing control system at the refinery.
At the same time, the enhanced high-performance process manager will triple
the capacity of the refinery's existing controllers.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the

Get the full Report on ALIOF - FREE

Get the full Report on BAYRY - FREE

Get the full Report on PFE - FREE

Get the full Report on GILD - FREE

Get the full Report on HON - FRE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.